Abbvie Deutschland Gmbh and Co Kg

Abbott Gmbh & Co Kg

Abbvie Inc.

Abbott Laboratories Corporation

Reinhold Mueller

Achim Moeller

Martin Schmidt

Roland Grandel

Wilfried Lubisch

Tariq Ghayur

Mario Mezler

Bernhard K Mueller

Nicole Teusch

Michael Kock

Sabine Schult

Eve H Barlow

Axel Meyer

Thomas Hoeger

Chung-Ming Hsieh

Heinz Hillen

Ulrich Ebert

Andreas R Striebinger

Jijie Gu

Volker Nimmrich

Enrico L Digiammarino

John E Harlan

Carsten Krantz

Gerard B Fox

Ralf Loebbert

Zhen Wu

Feng Luo

Wilfried Hornberger

Andreas Kling

Wilfried Martin Braje

Gerd Steiner

Wolfgang Wernet

Karla Drescher

Udo Lange

Helmut Mack

Karsten M Wicke

Thomas Subkowski

Uta Holzenkamp

Margaretha Bakker

Kurt Schellhaas

Bernhard K Muller

Gregor Schaffar

Wilfried Lubish

Bernhard K MÜLLER

The invention relates to neuromodulatory oligomers of the amyloid-&#x3b2;(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents. The invention further relates to derivatives of the oligomers and oligomers based on abbreviated forms of the amyloid-&#x3b2;(1-42) proteins, the production and use thereof.

Amyloid &#x3b2;(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

The invention concerns the identification and use of neogenin receptor-binding domains of members of the repulsive guidance molecule (RGM) protein family as well as polypeptide fragments derived therefrom. The inventive domains, i.e. peptide fragments are suited as agents for the active or passive immunization of individuals as well as diagnostic and therapeutic agents for use with diseases or pathological conditions in whose origin or progression, a member of the RGM family and a cellular receptor assigned to this molecule are involved. The invention also concerns monoclonal and polyclonal antibodies directed against the inventive binding domains and against the polypeptides derived therefrom, and to method for producing the inventive domains, polypeptides and antibodies.

Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR)

3-Substituted 3,4-dihydrothieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof. The invention relates to 3,4-dihydrothieno[2,3-d]pyrimidin-4-one derivatives which are substituted in position 3 by 5-membered heteroaryl which may be fused to an aryl or heteroaryl radical, where the heteroaryl and, if appropriate, the fused aryl or heteroaryl radical may have 1, 2 or 3 substituents selected independently of one another from C-alkyl, C-alkoxy, C-alkylthio, halogen, CN, halo-C-alkyl, halo-C-alkoxy, hydroxy, &#x2014;NH, &#x2014;N(R6), &#x2014;NH(R6), aryl, aryloxy, aralkyl, aralkyloxy and heteroaryl, where the substituents aryl, aryloxy, aralkyl, aralkyloxy and heteroaryl may have 1, 2 or 3 substituents selected independently of one another from C-alkyl, C-alkoxy, C-alkylthio, halogen, CN, halo-C-alkyl, halo-C-alkoxy, hydroxy, &#x2014;NH, &#x2014;N(R6)and &#x2014;NH(R6). The preparation and use of these derivatives, especially for therapeutic purposes, e.g. for the treatment of depressions, are likewise described.

3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof

The invention relates to compounds of the formula Iand the tautomeric forms, possible enantiomeric and diasteromeric forms thereof, and prodrugs thereof, and use thereof as PARP inhibitors.

Heterocyclic compounds and their use as PARP inhibitors

The invention relates to compounds of the formula Iand their tautomeric forms, possible enantiomeric and diastereomeric forms and their prodrugs, and to their preparation and use, where A, B, Rand Xhave the meanings given in the description.

Dibenzodiazepine derivatives, their preparation and use

Cyclo-alkyl substituted benzimidazoles and their use as PARP inhibitors

The present invention relates to novel benzimidazoles, their preparation and their use as inhibitors of the enzyme poly(ADP-ribose) polymerase or PARP (EC 2.4.2.30) for producing drugs.

Heterocyclically substituted benzimidazoles, the production and application thereof

Growing community of inventors

Schifferstadt, Germany

Reinhold Mueller